EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α‐Synuclein

Alina Schidlitzki, Milos Stanojlovic, Céline Fournier, Christopher Käufer, Malte Feja, Birthe Gericke, Marco Garzotti, Richard W D Welford, Michel Alexander Steiner, Elodie Angot, Franziska Richter iD

Movement Disorders · 2023

DOI: 10.1002/mds.29398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2023. Verfasst von Alina Schidlitzki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Hannover, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Synucleinopathies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Idorsia Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venglustat is a brain‐penetrant, small molecule inhibitor of glucosylceramide synthase used in clinical testing for treatment of Parkinson's disease (PD). Despite beneficial effects in certain cellular and rodent models, patients with PD with mutations in GBA , the gene for lysosomal glucocerebrosidase, experienced worsening of their motor function under venglustat treatment (NCT02906020, MOVES‐PD, phase 2 trial).

Objective

The objective of this study was to evaluate venglustat in mouse models of PD with overexpression of wild‐type α‐synuclein.

Methods

Mice overexpressing α‐synuclein (Thy1‐aSyn line 61) or Gba ‐mutated mice with viral vector‐induced overexpression of α‐synuclein in the substantia nigra were administered venglustat as food admixture. Motor and cognitive performance, α‐synuclein‐related pathology, and microgliosis were compared with untreated controls.

Results

Venglustat worsened motor function in Thy1‐aSyn transgenics on the challenging beam and the pole test. Although venglustat did not alter the cognitive deficit in the Y‐maze test, it alleviated anxiety‐related behavior in the novel object recognition test. Venglustat reduced soluble and membrane‐bound α‐synuclein in the striatum and phosphorylated α‐synuclein in limbic brain regions. Although venglustat reversed the loss of parvalbumin immunoreactivity in the basolateral amygdala, it tended to increase microgliosis and phosphorylated α‐synuclein in the substantia nigra. Furthermore, venglustat also partially worsened motor performance and tended to increase neurofilament light chain in the cerebrospinal fluid in the Gba ‐deficient model with nigral α‐synuclein overexpression and neurodegeneration.

Conclusions

Venglustat treatment in two mouse models of α‐synuclein overexpression showed that glucosylceramide synthase inhibition had differential detrimental or beneficial effects on behavior and neuropathology possibly related to brain region–specific effects. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseSynucleinopathiesMiceAnimalsalpha-SynucleinMice, TransgenicSubstantia NigraDisease Models, AnimalCarbamatesQuinuclidines

Stichwörter der Autor:innen

Parkinson's diseaseacid-β-glucosidasecognitionmotor behaviorneuroprotectionα-synuclein

Substanzen

alpha-SynucleinvenglustatCarbamatesQuinuclidines

Autor:innen und Institutionen

  • Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Hannover, Germany.
  • CNS Pharmacology and Drug Discovery, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
  • Roche Pharma Research and Early Development (pRED), F. Hoffman/La Roche Ltd, Basel, Switzerland.
  • Center for Systems Neuroscience Hannover, Hannover, Germany.
  • Matterhorn Biosciences AG, Basel, Switzerland.

ORCID-Profile: Franziska Richter

Förderung

  • Idorsia Pharmaceuticals

Zitieren

APA

Schidlitzki, A., Stanojlovic, M., Fournier, C., Käufer, C., Feja, M., Gericke, B., Garzotti, M., Welford, R. W. D., Steiner, M. A., Angot, E., & Richter, F. (2023). Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α‐Synuclein. Movement Disorders. https://doi.org/10.1002/mds.29398

Vancouver

Schidlitzki A, Stanojlovic M, Fournier C, Käufer C, Feja M, Gericke B, et al. Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α‐Synuclein. Movement Disorders. 2023. doi:10.1002/mds.29398

BibTeX
@article{Schidlitzki2023,
  author = {Schidlitzki, Alina and Stanojlovic, Milos and Fournier, Céline and Käufer, Christopher and Feja, Malte and Gericke, Birthe and Garzotti, Marco and Welford, Richard W D and Steiner, Michel Alexander and Angot, Elodie and Richter, Franziska},
  title = {Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α‐Synuclein},
  journal = {Movement Disorders},
  year = {2023},
  doi = {10.1002/mds.29398}
}
Kostenlos starten →